Dudediligence.

TG Therapeutics, Inc

TGTXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$83.9MSep ’24$108.2MDec ’24$120.9MMar ’25$141.1MJun ’25$161.7MSep ’25$192.6MDec ’25$204.9MMar ’26$240.3MJun ’26
Net income, by quarter
$3.9MSep ’24$23.3MDec ’24$5.1MMar ’25$28.2MJun ’25$390.9MSep ’25$23.0MDec ’25$19.8MMar ’26$7.8MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$6.7M$2.8M$233.7M$329.0M$616.3M
Gross profit$5.9M$2.5M$219.5M$290.5M$515.6M
Operating income−$344.8M−$218.3M$20.6M$41.9M$123.3M
Net income−$348.1M−$223.8M$12.7M$23.4M$447.2M
Operating cash flow−$295.6M−$176.2M−$31.4M−$40.5M−$24.8M
Free cash flow−$296.0M−$176.2M−$31.4M−$40.6M−$25.0M
Cash$298.9M$102.3M$92.9M$179.9M$79.1M
Debt$67.8M$71.1M$100.1M$244.4M$245.6M
Shares outstanding143.3M146.4M151.4M155.8M155.3M